Get the Stockscreener App
3.38
3.14%
-0.12
After Hours:
3.39
0.01
+0.30%
Lantern Pharma Inc stock is traded at $3.38, with a volume of 219.28K.
It is down -3.14% in the last 24 hours and up +37.80% over the past month.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
See More
Previous Close:
$3.50
Open:
$3.53
24h Volume:
219.28K
Relative Volume:
0.36
Market Cap:
$43.25M
Revenue:
-
Net Income/Loss:
$-17.12M
P/E Ratio:
-2.153
EPS:
-1.5699
Net Cash Flow:
$-15.68M
1W Performance:
+9.71%
1M Performance:
+37.80%
6M Performance:
-10.79%
1Y Performance:
+3.04%
1-Day Range:
$3.34
$3.70
1-Week Range:
$3.025
$3.70
52-Week Range:
$1.11
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.39 | 44.66M | 0 | -17.12M | -15.68M | -1.5699 |
VRTX
Vertex Pharmaceuticals Inc
|
436.05 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.30 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript - AOL.com
Lantern Pharma receives FDA clearance for trial amendments - Investing.com UK
Lantern Pharma receives FDA clearance for trial amendments By Investing.com - Investing.com South Africa
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC - BioSpace
Lantern Pharma (LTRN) Receives FDA Support for Phase 2 Trial - GuruFocus
Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC - TradingView
About Us - FinancialContent
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates - BioSpace
Lantern Pharma (LTRN) Q1 2026: EPS -$0.30 Beats Est. -$0.36; Rev - GuruFocus
Lantern Pharma Inc (LTRN) Stock Price, Quote, News & History - Benzinga
LANTERN PHARMA ($LTRN) Releases Q1 2026 Earnings - Quiver Quantitative
Lantern Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bios funds report 4.48% Lantern Pharma (NASDAQ: LTRN) stake - Stock Titan
Lantern Pharma (NASDAQ: LTRN) cuts R&D, advances oncology pipeline and AI spin-out - Stock Titan
Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lantern Pharma (NASDAQ: LTRN) raises $4.4M and plans withZeta.ai spinout - Stock Titan
Lantern Pharma Sees Funding Sufficient Until Mid-1Q27 >LTRN - Moomoo
Lantern Pharma Releases Q1 2025 Financial Results - AlphaStreet
Lantern Pharma Announces $9.25 Million Registered Direct Offering and Plans for Independent AI Entity with withZeta.ai 1 - Minichart
Why is Lantern Pharma stock soaring Monday? - MSN
Insider Buying: Lee Schalop Acquires 48,544 Shares of Lantern Ph - GuruFocus
Lantern Pharma raises capital, plans AI platform spinoff - TipRanks
Lantern Pharma Raises $4.4 Million in Registered Direct, Adds Private Warrants; Engages Rodman and Renshaw - TradingView
Lantern Pharma (NASDAQ: LTRN) closes $4.4M offering and outlines AI spin-out - Stock Titan
Lantern Pharma closes $4.4M registered direct offering - Investing.com
Lantern Pharma closes $4.4M registered direct offering By Investing.com - Investing.com Australia
Lantern Pharma (LTRN) director buys shares and long-dated warrants - Stock Titan
Lantern Pharma (LTRN) director adds shares and long-dated stock warrants - Stock Titan
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - Yahoo Finance
Lantern Pharma (NASDAQ: LTRN) sells 1.45M shares, pre-funded warrants included - Stock Titan
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - BioSpace
Lantern Pharma Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Lantern Pharma raises $4.4M in registered direct offering - Investing.com UK
Lantern Pharma Inc. announces up to $9.25 million registered direct offering with existing holders and a single institutional investor - marketscreener.com
Lantern Pharma raises $4.4M in registered direct offering By Investing.com - Investing.com Australia
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026 - BioSpace
Lantern Pharma (LTRN.US) will release its earnings report after the market closes on May 15. - Moomoo
Press Release: Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026 - Moomoo
What Lantern Pharma (LTRN) is doing to protect its market share (Trend Weakens) 2026-05-08Wall Street Picks - newser.com
Top pre-market gainers today — ELAB, ITRM, LTRN among stocks soaring before the bell - MSN
Lantern Pharma Inc. Unveils Roadmap for Withzeta.Ai with Launch of Zetaswarm and Zetaomics - marketscreener.com
Lantern Pharma Inc. 2025 Annual Report Amendment – Executive Compensation, Corporate Governance, and Audit Committee Details - Minichart
Lantern Pharma (NASDAQ: LTRN) details pay, ownership, options - Stock Titan
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery - MEXC Exchange
Lantern Pharma (LTRN) Introduces Advanced Molecular Intelligence Platform - GuruFocus
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KEYSER D JEFFREY | Director |
May 12 '26 |
Buy |
2.06 |
48,544 |
100,001 |
94,303 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):